Dihydroartemisinin-ursodeoxycholic acid conjugate is a potential treatment agent for inflammatory bowel disease.

[1]  Zhen-ye Xu,et al.  Study on the structure-activity relationship of dihydroartemisinin derivatives: Discovery, synthesis, and biological evaluation of dihydroartemisinin-bile acid conjugates as potential anticancer agents. , 2021, European journal of medicinal chemistry.

[2]  F. Oesch,et al.  The immunosuppressive activity of artemisinin‐type drugs towards inflammatory and autoimmune diseases , 2021, Medicinal research reviews.

[3]  Runyue Huang,et al.  Dihydroartemisinin ameliorates psoriatic skin inflammation and its relapse by diminishing CD8+ T-cell memory in wild-type and humanized mice , 2020, Theranostics.

[4]  W. Xu,et al.  Studies on the stereoselective synthesis and immunosuppressive activity of dihydroartemisinin-O-glycoside derivatives. , 2020, Bioorganic & medicinal chemistry letters.

[5]  Y. Tu,et al.  The birth of artemisinin. , 2020, Pharmacology & therapeutics.

[6]  Yu Cao,et al.  Artemisinin enhances the anti‐tumor immune response in 4T1 breast cancer cells in vitro and in vivo , 2019, International immunopharmacology.

[7]  R. Shrivastava,et al.  Current scenario of artemisinin and its analogues for antimalarial activity. , 2019, European journal of medicinal chemistry.

[8]  A. Menter,et al.  Anti-IL17 therapies for psoriasis , 2018, Expert opinion on biological therapy.

[9]  A. Menter,et al.  Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis , 2018, Therapeutic advances in chronic disease.

[10]  Wei Tang,et al.  Water-soluble artemisinin derivatives as promising therapeutic immunosuppressants of autoimmune diseases , 2017, Cellular & Molecular Immunology.

[11]  J. An,et al.  Antimalarial Drugs as Immune Modulators: New Mechanisms for Old Drugs. , 2017, Annual review of medicine.

[12]  Lifei Hou,et al.  Immune suppressive properties of artemisinin family drugs. , 2016, Pharmacology & therapeutics.

[13]  Leann Tilley,et al.  Artemisinin Action and Resistance in Plasmodium falciparum. , 2016, Trends in parasitology.

[14]  Jian-Ping Zuo,et al.  Therapeutic effects of the artemisinin analog SM934 on lupus-prone MRL/lpr mice via inhibition of TLR-triggered B-cell activation and plasma cell formation , 2015, Cellular and Molecular Immunology.

[15]  Bin Liu,et al.  Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum , 2015, Nature Communications.

[16]  Lifei Hou,et al.  Anti-Inflammatory and Immunoregulatory Functions of Artemisinin and Its Derivatives , 2015, Mediators of inflammation.

[17]  S. Gerondakis,et al.  NF-κB control of T cell development , 2013, Nature Immunology.

[18]  Lieping Chen,et al.  Molecular mechanisms of T cell co-stimulation and co-inhibition , 2013, Nature Reviews Immunology.

[19]  A. Hirao,et al.  PI3K-Akt-mTORC1-S6K1/2 axis controls Th17 differentiation by regulating Gfi1 expression and nuclear translocation of RORγ. , 2021, Cell reports.

[20]  Ya-Min Tsai,et al.  Antipsychotic drugs suppress the AKT/NF-κB pathway and regulate the differentiation of T-cell subsets. , 2011, Immunology letters.

[21]  A. Beg,et al.  The Th17 immune response is controlled by the Rel–RORγ–RORγT transcriptional axis , 2011, The Journal of experimental medicine.

[22]  Y. Tu.  The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine , 2011, Nature Medicine.

[23]  M. Ashraf,et al.  Artemisinins and immune system. , 2011, European journal of pharmacology.

[24]  Jian-Ping Zuo,et al.  Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses. , 2011, Arthritis and rheumatism.

[25]  H. Allgayer,et al.  First evidence that the antimalarial drug artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases , 2010, International journal of cancer.

[26]  Y. Li,et al.  SM934, a water-soluble derivative of arteminisin, exerts immunosuppressive functions in vitro and in vivo. , 2009, International immunopharmacology.

[27]  Y. Li,et al.  Investigation of the immunosuppressive activity of artemether on T‐cell activation and proliferation , 2007, British journal of pharmacology.

[28]  N. Perkins,et al.  Integrating cell-signalling pathways with NF-κB and IKK function , 2007, Nature Reviews Molecular Cell Biology.

[29]  T. Gilmore.  Introduction to NF-κB: players, pathways, perspectives , 2006, Oncogene.

[30]  U. Dianzani,et al.  Akt Is a Neutral Amplifier for Th Cell Differentiation* , 2004, Journal of Biological Chemistry.